Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_assertion type Assertion NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_head.
- NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_assertion description "[We analyzed erythroid response to erythropoetin (EPO) or darbepoetin (DAR) and thalidomide in MDS with 5q deletion treated by French centers (GFM) and in whom karyotype was successfully performed.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_provenance.
- NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_assertion evidence source_evidence_literature NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_provenance.
- NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_assertion SIO_000772 18191202 NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_provenance.
- NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_assertion wasDerivedFrom befree-20140225 NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_provenance.
- NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_assertion wasGeneratedBy ECO_0000203 NP529272.RAk2nhnL8dB6BkUrBhiVdsYjWBsLSl5pd0TFL8kEUMiwY130_provenance.